OBJECTIVE: To probe into the clinical characteristics

therapeutic regimens and possible mechanism of interstitial lung disease induced by oxaliplatin. METHODS: MEDLINE

PubMed

Web of Science

SpringerLink

Ovid

Embase

Wiley Oline Library

CNKI

Wanfang data and VIP database were retrieved to collect literature of interstitial lung disease induced by oxaliplatin

the retrieval time was from the establishment of the database to Apr. 2022. Patients’ general information

medication regimens

examination means

treatment and outcomes of the involved studies were extracted and analyzed descriptively. RESULTS: A total of 35 patients with interstitial lung disease induced by oxaliplatin were retrieved from 27 case reports; of which 26 were male and 9 were female; aged 30-79 years. Among the 35 patients

31 were treated with corticosteroids

of which 16 were improved and 15 were dead（including 14 male patients）. The association of adverse drug reactions was evaluated as “very likely”（24 patients） and “possible”（11 patients）. 19 patients were improved after drug withdrawal

dressing change and steroid hormone treatment

and no reoccurrence was observed during observation and follow-up periods. CONCLUSIONS: Interstitial lung disease induced by oxaliplatin occurs mostly in elderly male patients and has a higher mortality rate in male patients; which mostly occurs at a cumulative dose of oxaliplatin of 716.1 mg/m~2 over 8 cycles of drug combination. The lung function and imaging/radiology examination should be strengthened in patients treated with oxaliplatin

so as to detect adverse drug reactions as soon as possible and adjust the medication regimen in time.